AUTHOR=Ye Wei , Yao Min , Dong Yangchao , Ye Chuantao , Wang Dan , Liu He , Ma Hongwei , Zhang Hui , Qi Libin , Yang Yuewu , Wang Yuan , Zhang Liang , Cheng Linfeng , Lv Xin , Xu Zhikai , Lei Yingfeng , Zhang Fanglin 

TITLE=Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition

JOURNAL=Frontiers in Microbiology

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2020.01105

DOI=10.3389/fmicb.2020.01105

ISSN=1664-302X

ABSTRACT=<p>Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy. Thus, a therapeutic agent for the enterovirus-related disease is urgently needed. Remdesivir (GS-5734) is a novel monophosphoramidate adenosine analog prodrug that exhibits potent antiviral activity against diverse RNA virus families, including positive-sense <italic>Coronaviridae</italic> and <italic>Flaviviridae</italic> and negative-sense <italic>Filoviridae</italic>, <italic>Paramyxoviridae</italic>, and <italic>Pneumoviridae</italic>. Currently, remdesivir is under phase 3 clinical development for disease COVID-19 treatment. Here, we found that remdesivir impeded both EV71 viral RNA (vRNA) and complementary (cRNA) synthesis, indicating that EV71 replication is inhibited by the triphosphate (TP) form of remdesivir. Moreover, remdesivir showed potent antiviral activity against diverse enteroviruses. These data extend the remdesivir antiviral activity to enteroviruses and indicate that remdesivir is a promising antiviral treatment for EV71 and other enterovirus infections.</p>